DeepMed Research

NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease

Not Applicable

Active, not recruiting

Conditions: Acute Coronary Syndromes

Interventions: Procedure: Intravascular ultrasound
Procedure: MRI

First Posted Date: 2008-11-25

Last Posted Date: 2024-08-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 50

Registration Number: NCT00798122

Locations: 🇺🇸
NYU Medical Center and Bellevue Hospital Center, New York, New York, United States

High Water Intake to Slow Progression of Polycystic Kidney Disease

Not Applicable

Completed

Conditions: Kidney, Polycystic, Autosomal Dominant

Interventions: Other: Water

First Posted Date: 2008-11-02

Last Posted Date: 2016-04-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 23

Registration Number: NCT00784030

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States

Feasibility of "At-home" Titration of Solifenacin

Phase 4

Terminated

Conditions: Overactive Bladder

Interventions: Drug: Solifenacin

First Posted Date: 2008-09-25

Last Posted Date: 2015-10-26

Lead Sponsor: NYU Langone Health

Target Recruit Count: 36

Registration Number: NCT00759577

Study of Wound Packing After Superficial Skin Abscess Drainage

Phase 4

Completed

Conditions: Abscess
Skin Diseases, Infectious
Boils
Furuncle
Carbuncle
Folliculitis
Cellulitis
Wounds

Interventions: Procedure: NoPacking
Procedure: Wound packing

First Posted Date: 2008-09-03

Last Posted Date: 2011-01-04

Lead Sponsor: NYU Langone Health

Target Recruit Count: 60

Registration Number: NCT00746109

Locations: 🇺🇸
New York University / Bellevue Hospital Center, NY, New York, United States

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

Phase 1

Completed

Conditions: Discoid Lupus Erythematosus

Interventions: Drug: CC-10004

First Posted Date: 2008-07-03

Last Posted Date: 2021-03-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00708916

Locations: 🇺🇸
New York University Tisch Hospital, New York, New York, United States

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Erlotinib
Drug: Sorafenib

First Posted Date: 2008-06-13

Last Posted Date: 2016-06-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 45

Registration Number: NCT00696696

Locations: 🇺🇸
Desert Regional Medical Center, Palm Springs, California, United States
🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
New York University Cancer Center, New York, New York, United States

Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Lidocaine

First Posted Date: 2008-05-21

Last Posted Date: 2009-02-06

Lead Sponsor: NYU Langone Health

Target Recruit Count: 150

Registration Number: NCT00681902

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Phase 1

Withdrawn

Conditions: Ovarian Carcinoma

First Posted Date: 2008-04-16

Last Posted Date: 2015-03-18

Lead Sponsor: NYU Langone Health

Registration Number: NCT00659399

Locations: 🇺🇸
NYU Cancer Institute Clinical Cancer Center, New York, New York, United States

Acupuncture for Nausea in HIV

Phase 2

Completed

Conditions: HIV Infections

Interventions: Other: Acupuncture
Other: Sham Acup
Other: Individualized Acup based on TCM diagnosis

First Posted Date: 2008-02-27

Last Posted Date: 2012-06-22

Lead Sponsor: NYU Langone Health

Target Recruit Count: 159

Registration Number: NCT00624793

Extended-release Naltrexone for Alcohol Dependence in Primary Care

Phase 4

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Extended release injectable naltrexone (Vivitrol)

First Posted Date: 2008-02-21

Last Posted Date: 2011-09-27

Lead Sponsor: NYU Langone Health

Target Recruit Count: 72

Registration Number: NCT00620750

Locations: 🇺🇸
NYU School of Medicine, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy